corporate program · canadian blood and marrow transplant group société canadienne de greffe de...

Canadian Blood and Marrow Transplant GroupSociété canadienne de greffe de cellules souches hématopoïétiques

corporate program

WINN pegForT Garry HoTelapril 10 to april 13, 2013

2013

Canadian Blood and Marrow TransplanT Group

annual ConferenCe

3

T: 604-874-4944 • F: 604-874-4378 • E: [email protected] • W: www.cbmtg.org

Table of ContentsSponsor Listing ...........................................................................................5

Sponsored Symposia Schedule .....................................................................6

Sponsored Symposia Descriptions ...............................................................7

Exhibitor Floorplan and List ......................................................................11

Exhibitor Descriptions ...............................................................................12

JanssenDASH_4.indd 1 5/11/11 2:49:18 PM


annual ConferenCe

5


JanssenDASH_4.indd 1 5/11/11 2:49:18 PM

Sponsors ListingWe would like to thank the sponsors of the Canadian Blood and Marrow Transplant Group Annual Meeting 2013; the conference is made possible through generous support of the following companies:

Platinum Sponsors

Gold Sponsors

Silver Sponsors

Conference Contributors

Symposia Supporters

Conference Exhibitors

We wish to thank the following companies for their support of the Wet Lab

Astellas Pharma Canada, Inc. • Bristol-Myers Squibb Canada • Celgene Inc. • CSL Behring • Digi-Trax Corporation • Hoffmann-La Roche • Janssen Inc. • LabWare Inc. • Lundbeck • Merck • Novartis Pharmaceuticals Canada Inc. • Otsuka Canada Pharmaceuticals Inc. • Pfizer Canada • Sanofi Oncology • STEMSOFT Software Inc. • Terumo BCT

WINN peg2013

APriL 10 – APriL 13, 2013 Fort GArry HotEL

6

CBMTG AnnuAl ConferenCe • fort Garry Hotel, Winnipeg MB • April 10th – 13th, 2013

Sponsored Symposia Schedule

Pre-conference Day – Wednesday, april 10, 20131300 - 1700 WET LAB

tour and wet lab BD, Biosafe, Héma-Québec, Health Sciences Centre Winnipeg, STEMCELLTechnologies • Health Sciences Centre Winnipeg

1930 – 2130 DINNER SyMPOSIuM

optimizing the treatment of transplant-eligible patients in multiple myeloma Janssen Inc. • Grand Ballroom,4th Floor Conference Centre

Day one – Thursday, april 11, 20130730 – 0845 BREAkFAST SyMPOSIuM

Myelofibrosis – insights into the disease, its management and treatment optionsNovartis Pharmaceuticals Canada Inc. • Grand Ballroom,4th Floor Conference Centre

1230 – 1400 LuNCH SyMPOSIuM

Stem cell mobilization for autologous transplantation: Where are we and how do we get to optimal practice?Sanofi Oncology • Grand Ballroom,4th Floor Conference Centre

1830 – 2030 DINNER SyMPOSIuM

Home therapy with subcutaneous immunoglobulins for patients with secondary immunodeficiencyCSL Behring • Grand Ballroom,4th Floor Conference Centre

Day Two – Friday, april 12, 2013

0730 – 0915 BREAkFAST SyMPOSIuM

Evidence-based treatment of CML: Patients firstBristol-Myers Squibb Canada • Grand Ballroom,4th Floor Conference Centre

1230 – 1400 LuNCH SyMPOSIuM

the role of novel agents for iNHL in the transplant settingLundbeck • Grand Ballroom,4th Floor Conference Centre

Day 3 – Saturday, april 13, 20130730 – 0900 BREAkFAST SyMPOSIuM

the complement system: role in disease, laboratory assessment and directed therapyAlexion • Grand Ballroom,4th Floor Conference Centre


annual ConferenCe

7


Sponsored Symposia Descriptions

Pre-Conference Day – Wednesday, April 10, 2013

DINNER SyMPOSIuM 1930 to 2130 • GrAND BALLrooM 4tH FLoor, CoNFErENCE CENtrE

oPtiMiziNG tHE trEAtMENt oF trANSPLANt-ELiGiBLE PAtiENtS iN MuLtiPLE MyELoMA CHAIR: Ade Olujohungbe, Dip. Haem (Lond), MD, FRCP, FRCPath, Associate Professor of Hematology, CancerCare Manitoba

SPEAKER: Joseph Mikhael, MD, MEd, FRCPC, FACP, Consultant Hematologist, Mayo Clinic Arizona, Associate Chair of Education,

Department of Medicine, Program Director, Hematology-oncology Fellowship, Associate Professor, Mayo College of Medicine

oBJectIVeS: Through a review of the most recent evidence and sharing of patient experience, this educational program will endeavor to:

1. Review current best practices in the treatment of patients with Multiple Myeloma prior to receiving a stem cell transplant

2. Explore the role of novel strategies post-transplant in achieving better patient outcomes to treatment

3. Discuss the management and optimal treatment sequencing for patients who have relapsed following a stem cell transplant

Day one – thursday, April 11, 2013

BREAkFAST SyMPOSIuM 0730 to 0845 GrAND BALLrooM 4tH FLoor, CoNFErENCE CENtrE

MyELoFiBroSiS – iNSiGHtS iNto tHE DiSEASE, itS MANAGEMENt AND trEAtMENt oPtioNS

This educational event will provide an opportunity to assess the ways that Janus kinase (JAk) inhibitors are shaping the management of myelofibrosis in both curative and palliative settings. Dr. Brian Leber from McMaster university and Dr. Lynda Foltz from the university of British Columbia will discuss recent clinical evidence and developments in this rapidly evolving therapeutic field. At the end of this session, participants will be able to:

• Discuss the emerging role of JAk inhibitors in the management of myelofibrosis• Define candidates for transplant and pre-transplant therapy in the era of JAk inhibitors• Recognize additional benefits of JAk inhibitors associated with reduction in splenomegaly and improvement in constitutional

symptoms

Please join us as we navigate through recent advances in the management of myelofibrosis.

WINN peg2013


8


Day one – thursday, April 11, 2013 (continued)

LuNCH SyMPOSIuM 1230 to 1400 GrAND BALLrooM 4tH FLoor, CoNFErENCE CENtrE

StEM CELL MoBiLizAtioN For AutoLoGouS trANSPLANtAtioN: WHErE ArE WE AND HoW Do WE GEt to oPtiMAL PrACtiCE?Christopher Bredeson, MD MSc(Epi) FRCPC, Head, Malignant Hematology and Stem Cell transplantation, the ottawa Hospital, Senior

Scientist, ottawa Hospital research institute, Professor, Division of Hematology, the university of ottawa

Jason Tay, BA MB BCh. BAO MSc(Epi) FRCP(C), Clinical Hematologist, the ottawa Hospital, Clinician Scientist, ottawa Hospital research

institute, Asst Professor of Medicine, the university of ottawa

oBJectIVeS:

At the end of the seminar the audience will:

1. Be familiar with the current Canadian landscape regarding the approach to collection of autologous hematopoietic stem cells2. Be familiar with the data supporting different ways in which Mozobil has been used to facilitate autologous hematopoietic stem

cell collection3. Be familiar with the planned “Canadian context” decision analysis regarding autologous hematopoietic stem cell collection

case Based Discussions: After some brief introductory and background slides, the session will use a series of short clinical vignettes to discuss clinical practice variation and the relevant data regarding approaches to autologous hematopoietic stem cell mobilization. The ultimate goal will be to introduce the investigator initiated “Canadian context” decision analysis to determine the optimal approach to mobilizing autologous hematopoietic cell grafts.

Each case would include at least one audience survey question as to how they would approach the issue.

DINNER SyMPOSIuM 1830 to 2030 GrAND BALLrooM 4tH FLoor, CoNFErENCE CENtrE

HoME tHErAPy WitH SuBCutANEouS iMMuNoGLoBuLiNS For PAtiENtS WitH SECoNDAry iMMuNoDEFiCiENCyElie Haddad, MD, PhD, Professor of Pediatrics, university of Montreal, Head, Pediatric immunology and rheumatology Division, Sainte-

Justine Hospital, Montreal

oBJectIVeS:

• A review of efficacy data of subcutaneous immunoglobulins in both primary and secondary immunodeficiencies • Discuss the convenience and quality of life issues related to home therapy with patient suffering from secondary

immunodeficiencies• Present and discuss the Sainte Justine Hospital cohort of secondary immunodeficiency patients treated with home subcutaneous

immunoglobulins


annual ConferenCe

9


Day two – Friday, April 12, 2013


EviDENCE-BASED trEAtMENt oF CML: PAtiENtS FirStJeffrey H. Lipton, PhD, MD, FRCPC, Professor of Medicine, Princess Margaret Hospital, university of toronto, toronto, ontario

Pierre Laneuville, MD, Associate Professor, Medicine and oncology, McGill university Health Center, McGill university, Montreal, Quebec

Philipp Le Coutre, MD, PhD, Department of Hematology, oncology and tumor immunology, Charité- universitätsmedizin Berlin,

(university of Medicine Berlin)

SympoSIum DeScrIptIoN:

This symposium provides an overview of the data supporting the use of second-generation tyrosine kinase inhibitors (TkIs: dasatinib and nilotinib) for the treatment of chronic myeloid leukemia (CML). The session will emphasize the importance of selecting the appropriate treatment agent to optimize long-term outcomes for CML patients.

oBJectIVeS:

At the conclusion of this symposium, participants should be able to:

1. use evidence-based medicine to select the best TkI for individual patients 2. Discuss new and emerging data on TkI safety3. Discuss implications of impending generic TkI therapy

ageNDa

7:30 – 7:45 am Breakfast7:45 – 8:00 am Introduction (Dr. Jeffrey Lipton)8:00 – 8:40 am Discussion of Efficacy and New Emerging Safety Data in Choosing an Appropriate TkI for CML Patients (Dr. Philipp Le Coutre)8:40 – 9:00 am Overview of Generics and Implications in CML (Dr. Pierrre Laneuville)9:00 – 9:15 am Patient Cases & Wrap-up (Dr. Jeffrey Lipton).

LuNCH SyMPOSIuM 1230 to 1400 GrAND BALLrooM 4tH FLoor, CoNFErENCE CENtrE

tHE roLE oF NovEL AGENtS For iNHL iN tHE trANSPLANt SEttiNGPierre Laneuville, MD, FRCPC, Hematologist, McGill university Health Centre, Montreal, Quebec

Douglas Stewart, MD, FRCPC, Chief, Division of Hematology & Hematologic Malignancies, university of Calgary, Calgary, Alberta

This interactive symposium aims at addressing the impact of novel agents and treatment strategies on the use of hematopoietic stem cell transplantation (HSCT) in the management of iNHL.

WINN peg2013


10


Through the use of touchpads, the participants will be able to weigh-in on the discussion of two patient cases where new evidence is contrasted with present standard of care and discussion centers on experience-consensus in a New Era of iNHL Patient Management.

oBJectIVeS:

At the end of this session, participants should be able to:

• Evaluate the role of new therapies for iNHL within current standard treatment algorithms• use optimal therapy for iNHL, including HSCT, based on the latest scientific evidence• Recognize the potential impact of novel treatments on the use of HSCT

program ageNDa

12:30 – 12:40 Arrivals and Seating (Buffet Lunch) 12:40 – 12:50 Welcome and Overview 12:40 – 1:00 Presentation and Case #1: Evolving Management of iNHL & Auto HSCT 1:00 – 1:15 Expert commentary / Q&A 1:15 – 1:35 Presentation and Case #2 : Evolving Management of iNHL & Allo HSCT 1:35 – 1:50 Expert commentary / Q&A 1:50 – 2:00 Closing remarks

Day three – Saturday, April 13, 2013


tHE CoMPLEMENt SyStEM: roLE iN DiSEASE, LABorAtory ASSESSMENt AND DirECtED tHErAPyEric Wagner, PhD, D(ABHI), immunology and Histocompatibility laboratory, CHu de Quebec-CHuL, Quebec, QC, Associate Professor,

Department of Microbiology-infectiology and immunology, Faculty of Medicine, Laval university, Quebec, QC

oBJectIVeS

1. Review complement activation pathways, interplay with other systems and regulation of activation

2. Identify clinical settings associated with complement deficiency or dysregulation

3. Determine which clinical tests are available and required in selected clinical settings

4. Review complement-directed therapeutic agents and their usefulness in clinical settings.


annual ConferenCe

11


Exhibitor Listing & Floor PlanAstellas Pharma Canada, Inc. 05

Bristol-Myers Squibb Canada 09

Celgene Inc. 08

CSL Behring 02

Digi-Trax Corporation 15

Hoffmann-La Roche 13

Janssen Inc. 14

LabWare Inc. 16

Lundbeck Canada, Inc. 12

Merck Canada 04

Novartis Pharmaceuticals Canada Inc. 11

Otsuka Canada Pharmaceuticals Inc. 01

Pfizer Canada Inc. 07

Sanofi Oncology 10

Stemsoft Software Inc. 03

TerumoBCT 06

Exhibits Hours Exhibits are located in Assinibone Combined, 5th Floor, Conference Centre.

Wednesday, april 10, 2013 1800 – 1930

thursday, april 11, 2013 0900 – 1645

Friday, april 12, 2013 1030 – 1800

123

4

5

6

7

8 9 10

11

1213

14

15

16

WINN peg2013


12


Exhibitor Description

ASTELLAS PHARMA CANADA, INC. 05

Astellas Pharma Canada, Inc. is a Canadian affiliate of Tokyo-based Astellas Pharma Inc. Astellas is a pharmaceutical company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceutical products. In Canada, Astellas has an intense commercial focus on five therapeutic areas - urology, Immunology, Infectious Disease, Dermatology and Oncology. Visit: www.astellas.ca

BRISTOL-MyERS SQuIBB CANADA 09

Bristol-Myers Squibb is a global biopharmaceutical company firmly committed to a single Mission — to discover, develop and deliver innovative medicines that help patients prevail over serious diseases.

Bristol-Myers Squibb has a unique BioPharma strategy which combines the reach and resources of a major pharmaceutical company with the entrepreneurial spirit and agility of a successful biotech company.

In the past decade, Bristol-Myers Squibb has launched ten new products for Canadians in need, including medicines for cancer, heart disease, diabetes, HIV/AIDS, rheumatoid arthritis, hepatitis B and psychiatric disorders.

http://www.bmscanada.ca

CELGENE INC. 08

Celgene Inc is part of a global, integrated, biopharmaceutical company primarily engaged in the discovery, development and commercialization of innovative therapies designed to treat cancer and immune-inflammatory related diseases.

CSL BEHRING 02

privigen: Privigen, Immune Globulin Intravenous (Human), is a ready-to-use, sterile, 10% protein liquid preparation of polyvalent human immunoglobulin G (IgG) for intravenous administration. Privigen (Immune Globulin Intravenous (Human)) is indicated for:

• The treatment of patients with primary immune deficiency (PID) and secondary immune deficiency (SID). This includes, but is not limited to, common variable immunodeficiency (CVID), X-linked agammaglobulinemia, congenital agammaglobulinemia, secondary hypogammaglobulinemia, Wiskott-Aldrich syndrome, and severe combined immunodeficiencies.

• The treatment of patients with immune thrombocytopenic purpura (ITP) to rapidly raise platelet counts to prevent bleeding.

Hizentra: Hizentra, Subcutaneous Immune Globulin (Human) (SCIG), is a ready to use, polyvalent human normal immunoglobulin G (IgG) for subcutaneous administration. Hizentra is a 20% protein solution. Hizentra, Subcutaneous Immune Globulin


annual ConferenCe

13


(Human) (SCIG), is indicated for the treatment of patients with primary immune deficiency (PID) and secondary immune deficiency (SID) who require immune globulin replacement therapy.

DIGI-TRAX CORPORATION 15

Digi-Trax Corporation®, offers an extensive product line for the blood bank marketplace – specifically for hospital transfusion services, independent donor centers, and facilities that perform cell therapy, cord blood banking, and bone marrow transplants. We deliver quality software, printers, scanners, labels, technical service and support. Digi-Trax leads the way in providing products that meet all ISBT 128 bar code standards.

HOFFMANN-LA ROCHE 13

Hoffmann-La Roche is recognized as a global leader in providing pharmaceutical and diagnostic solutions that make a profound difference in people’s lives. As an innovator of products and services for the early detection, prevention, diagnosis and treatment of acute and long-term diseases, Hoffmann-La Roche contributes on a broad range of fronts to improving people’s health and quality of life.

As an integral part of the health care team, oncologists and hematologists are respected and recognized for the extensive knowledge and value they provide in clinical practice. With a sincere commitment to, and belief in the importance of continuing education, Hoffmann-La Roche is proud to sponsor the Canadian Blood and Marrow Transplant Group Conference 2013.

JANSSEN INC. 14

VELCADE® is a novel, first-in-class proteasome inhibitor that is used for the treatment of adult patients with:

1. Previously untreated Multiple Myeloma (MM) who are unsuitable for stem cell transplantation as part of combination therapy.

2. Relapsed MM.

3. Mantle cell lymphoma. Mantle cell lymphoma is a type of non- Hodgkin’s lymphoma which is a cancer of the blood that affects the white blood cells.

EPREX® is indicated for the treatment of anemia due to the effect of concomitantly administered chemotherapy based on studies that have shown a reduction in the need for RBC transfusions in patients with advanced or metastatic, non-myeloid malignancies receiving chemotherapy for a minimum of two months.

LABWARE INC. 16

LabWare Inc. provides a proven GxP compliant LIS solution for the clinical market. In addition, our pharmaceutical experience has enabled compliance with the FDA’s 21 CFR Part 11 regulation for Electronic Records and Signatures. LabWare cellular therapy customers include Seattle Cancer Care and the City of Hope.

WINN peg2013


14


LuNDBECk CANADA, INC. 12

Montreal-based Lundbeck Canada, proud sponsor of 2013 CBMTG Meeting, is a subsidiary of Lundbeck A/S, a leading international research-based pharmaceutical company.

For more than a decade, Lundbeck has been a respected leader in developing and bringing Central Nervous System disorder treatments to Canadians in a way that reflects our Danish origins of respecting every individual and taking care of one another. It is with this mindset that Lundbeck is bringing new Oncology treatments to Canada , wishing to give hope, strength and humanity to Canadian cancer patients. Visit us at Lundbeck.ca

MERCk CANADA 04

Today’s Merck is working to help the world be well. In Canada, Merck markets over 530 pharmaceutical, consumer and animal health products. Merck is a leader in a broad range of areas such as cardiology, infectious diseases, respiratory, vaccines, women’s health, virology, oncology and diabetes. For more information, visit www.merck.ca.

NOVARTIS PHARMACEuTICALS CANADA INC. 11

Novartis Oncology has emerged as a global leader in oncology through targeted research and open partnership in the pursuit

of new therapies capable of transforming outcomes for people with cancer.

We offer a wide range of innovative therapies to help physicians meet patient needs, with one of the broadest pipelines in the industry. Our research is driven by a distinctive scientific and clinical strategy, focusing on unmet medical needs and disease pathways. For more information visit www.novartisoncology.com.

OTSukA CANADA PHARMACEuTICALS INC. 01

Guided by a global perspective and determined to contribute to better health for people worldwide, Otsuka Pharmaceutical Co. is committed to leveraging its original ideas and technology development prowess to create innovative pharmaceutical products that address unmet needs in medical care. We are also determined to communicate the real value of our products to customers. All of this is part of our mission to promote better health for people worldwide.

PFIzER CANADA INC. 07

Pfizer Canada Inc. is the Canadian operation of Pfizer Inc, the world’s leading biopharmaceutical company. Pfizer discovers, develops, manufactures and markets prescription medicines and vaccines for humans. At Pfizer, we’re working together for a healthier world. For more information, visit www.pfizer.ca


annual ConferenCe

15


SANOFI ONCOLOGy 10

Sanofi Oncology is dedicated to translating science into effective therapeutics that address unmet medical needs for cancer and organ transplant patients. Starting with a deep understanding of the disease and the patient, Sanofi Oncology employs innovative approaches to drug discovery and clinical development, with the ultimate goal of bringing the right medicines to the right patients to help them live healthier and longer lives. We believe in the value of partnerships that combine our internal scientific expertise with that of industry and academic experts. Our portfolio includes 10 marketed products and more than 15 investigational compounds in clinical development, including small molecules and biological agents.

Sanofi, a global and diversified healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients’ needs. Sanofi has core strengths in the field of healthcare with seven growth platforms: diabetes solutions, human vaccines, innovative drugs, consumer healthcare, emerging markets, animal health and the new Genzyme. Sanofi is listed in Paris (EuRONEXT: SAN) and in New york (NySE: SNy).

Sanofi companies in Canada include Sanofi Canada (pharmaceuticals), Sanofi Pasteur (vaccines), Sanofi Consumer Health (health and beauty), Genzyme (rare diseases) and Merial (animal health). Together they employ more than 1,700 people across the country. In 2011 Sanofi companies invested $151.7 million in R&D in Canada, creating jobs, business and opportunity throughout the country.

STEMSOFT SOFTWARE INC. 03

STEMSOFT, a proud partner of the CBMTG National Registry, offers the industry’s leading clinical and laboratory software solutions designed exclusively for the cell therapy workflow. NEW! STEMSOFTconnect: REGISTRy – streamline your CIBMTR reporting process by seamlessly uploading applicable STEMSOFT data to FormsNet. Visit the STEMSOFT booth today to learn how we can save you time, increase access to a full dataset and improve compliance in your program. STEMSOFT Software Inc.

track | share | grow | 1-800-671-3234 | [email protected] | www.stemsoft.com

TERuMO BCT 06

Terumo BCT, a global leader in blood component, therapeutic apheresis and cellular technologies, is the only company with the unique combination of apheresis collections, manual and automated whole blood processing, and pathogen reduction coupled with leading technologies in therapeutic apheresis and cell processing. We believe in the potential of blood to do even more for patients than it does today. This belief inspires our innovation and strengthens our collaboration with customers. Terumo BCT—unlocking the Potential of Blood.

CBMTG - Corporate AD - 2013-frd.pdf 1 13/03/13 11:05

June 11 to 14, 2014The Westin Nova Scotian • Halifax, NS

www.CBMTG.ORG

Annual Conference of the Canadian Blood and Marrow Transplant GroupAn educational conference for professionals in the field of Blood and Marrow Transplantation

CBMTG Head OffiCe375 West 5th Avenue, Suite 201Vancouver, BC V5Y 1J6T: 604-874-4944F: 604-874-4378E: [email protected]: www.cbmtg.org

The Canadian Blood and Marrow Transplant Group Conference 2014June 11 to 14, 2014, The westin Nova Scotian, Halifax, NS

We invite all BMT health care professionals to attend our conference in Halifax in 2014.

The conference planning committee, led by Dr. Stephen Couban, is finalizing an exciting program that will feature presentations on latest developments in BMT patient care and clinical and laboratory research breakthroughs.

The format of the 2014 CBMTG conference will include scientific plenary sessions, keynote presentations, multi-disciplinary and discipline-specific sessions, oral research presentations, committee and society meetings and corporate satellite sessions.

corporate program · canadian blood and marrow transplant group société canadienne de greffe de...

Documents